source
- FDA approves Roivant's oral dermatomyositis drug Lisraya (brepocitinib)The U.S. Food and Drug Administration has granted approval to Roivant's drug brepocitinib, which will be sold under the brand name Lisraya. The decision marks the first major regulatory clearance f…
- Moderna raises $2 billion after Phase 3 success of its algorithm-driven personalized cancer vaccine with MerckModerna announced a $2 billion convertible debt financing, a move that follows the Phase 3 success of its personalized cancer vaccine developed with Merck. The vaccine relies on software that scan…